Darsh Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 5.25 Cr
as on 17-07-2024
- Paid Up Capital ₹ 4.90 Cr
as on 17-07-2024
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.76 Cr
as on 17-07-2024
- Satisfied Charges ₹ 14.94 Cr
as on 17-07-2024
- Revenue 15.03%
(FY 2023)
- Profit -38.28%
(FY 2023)
- Ebitda 11.78%
(FY 2023)
- Net Worth 2.13%
(FY 2023)
- Total Assets -13.33%
(FY 2023)
About Darsh Pharmachem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.25 Cr and a paid-up capital of Rs 4.90 Cr.
The company currently has active open charges totaling ₹8.76 Cr. The company has closed loans amounting to ₹14.94 Cr, as per Ministry of Corporate Affairs (MCA) records.
Himanshukumar Patel, Ramnikbhai Patel, Jaimini Patel, and One other member serve as directors at the Company.
- CIN/LLPIN
U24309GJ2016PTC091721
- Company No.
091721
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Apr 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Mahemdabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Darsh Pharmachem?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sureshbhai Patel  | Director | 29-Jan-2018 | Current |
| Himanshukumar Patel | Director | 28-Apr-2016 | Current |
| Ramnikbhai Patel | Director | 28-Apr-2016 | Current |
| Jaimini Patel | Director | 11-Oct-2021 | Current |
Financial Performance and Corporate Structure Insights of Darsh Pharmachem.
Darsh Pharmachem Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 15.03% increase. The company also saw a substantial fall in profitability, with a 38.28% decrease in profit. The company's net worth moved up by a moderate rise of 2.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Darsh Pharmachem?
In 2023, Darsh Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
3 years 6 months Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 23 Oct 2023 | ₹2.22 Cr | Open |
Sidbi Creation Date: 29 Dec 2021 | ₹3.00 Cr | Open |
Others Creation Date: 30 Nov 2021 | ₹1.64 Cr | Open |
How Many Employees Work at Darsh Pharmachem?
Darsh Pharmachem has a workforce of 29 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Jun 15, 2019, Darsh Pharmachem has raised a total of ₹ 6.5 Cr, with the most recent deal valued at ₹ 1.9 Cr. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
